MX2023005211A - Proteina quimerica que comprende el dominio de union al receptor de la proteina de la espiga de coronavirus y composiciones que las comprenden. - Google Patents
Proteina quimerica que comprende el dominio de union al receptor de la proteina de la espiga de coronavirus y composiciones que las comprenden.Info
- Publication number
- MX2023005211A MX2023005211A MX2023005211A MX2023005211A MX2023005211A MX 2023005211 A MX2023005211 A MX 2023005211A MX 2023005211 A MX2023005211 A MX 2023005211A MX 2023005211 A MX2023005211 A MX 2023005211A MX 2023005211 A MX2023005211 A MX 2023005211A
- Authority
- MX
- Mexico
- Prior art keywords
- chimeric protein
- protein
- coronavirus
- binding domain
- receptor binding
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title abstract 5
- 108020001507 fusion proteins Proteins 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 3
- 108010061994 Coronavirus Spike Glycoprotein Proteins 0.000 title abstract 2
- 102000005962 receptors Human genes 0.000 title abstract 2
- 108020003175 receptors Proteins 0.000 title abstract 2
- 241000711573 Coronaviridae Species 0.000 abstract 2
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- 241000700721 Hepatitis B virus Species 0.000 abstract 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 abstract 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000002105 nanoparticle Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 125000006850 spacer group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20071—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU2020000081A CU24665B1 (es) | 2020-11-04 | 2020-11-04 | Proteína quimérica que comprende el dominio de unión al receptor de la proteína de la espiga de coronavirus y composiciones que las comprenden |
| PCT/CU2021/050010 WO2022096039A1 (es) | 2020-11-04 | 2021-11-03 | Proteina quimerica que comprende el dominio de union al receptor de la proteina de la espiga de corona virus y composiciones que las comprenden |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023005211A true MX2023005211A (es) | 2023-05-16 |
Family
ID=79164940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023005211A MX2023005211A (es) | 2020-11-04 | 2021-11-03 | Proteina quimerica que comprende el dominio de union al receptor de la proteina de la espiga de coronavirus y composiciones que las comprenden. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230405106A1 (enExample) |
| EP (1) | EP4242222A1 (enExample) |
| JP (1) | JP2023548205A (enExample) |
| CN (1) | CN116802194A (enExample) |
| AR (1) | AR123998A1 (enExample) |
| AU (1) | AU2021373188A1 (enExample) |
| CA (1) | CA3197024A1 (enExample) |
| CO (1) | CO2023004963A2 (enExample) |
| CU (1) | CU24665B1 (enExample) |
| MX (1) | MX2023005211A (enExample) |
| WO (1) | WO2022096039A1 (enExample) |
| ZA (1) | ZA202304779B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7887978B2 (ja) * | 2022-05-23 | 2026-07-10 | バクスディグム カンパニー，リミティド | ウイルスヌクレオカプシドを用いた結晶性タンパク質ベースの標的タンパク質融合自己組織化ナノ粒子製造プラットフォーム |
| KR102617592B1 (ko) * | 2022-05-23 | 2023-12-29 | 주식회사 백스다임 | 바이러스 뉴클레오캡시드를 이용한 오량체형 독소 단백질 기반 목적 단백질 융합 오량체 제조 플랫폼 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111217918B (zh) * | 2020-03-04 | 2020-11-10 | 中山大学 | 一种基于2,4-二氧四氢喋啶合酶的新型冠状病毒s蛋白双区域亚单位纳米疫苗 |
| CN111366734B (zh) * | 2020-03-20 | 2021-07-13 | 广州市康润生物科技有限公司 | 双指标筛选新冠病毒及预判重型肺炎的方法 |
| CN111620952A (zh) * | 2020-06-17 | 2020-09-04 | 苏州米迪生物技术有限公司 | 基于嵌合型病毒样颗粒的新型冠状病毒疫苗 |
| CN111676248A (zh) * | 2020-07-02 | 2020-09-18 | 军事科学院军事医学研究院军事兽医研究所 | 表达新型冠状病毒S基因与流感M1基因嵌合SARS-CoV-2 VLP的构建 |
-
2020
- 2020-11-04 CU CU2020000081A patent/CU24665B1/es unknown
-
2021
- 2021-11-03 JP JP2023527114A patent/JP2023548205A/ja active Pending
- 2021-11-03 MX MX2023005211A patent/MX2023005211A/es unknown
- 2021-11-03 WO PCT/CU2021/050010 patent/WO2022096039A1/es not_active Ceased
- 2021-11-03 CA CA3197024A patent/CA3197024A1/en active Pending
- 2021-11-03 CN CN202180088951.7A patent/CN116802194A/zh active Pending
- 2021-11-03 EP EP21834711.0A patent/EP4242222A1/en active Pending
- 2021-11-03 US US18/035,254 patent/US20230405106A1/en active Pending
- 2021-11-03 AU AU2021373188A patent/AU2021373188A1/en not_active Abandoned
- 2021-11-04 AR ARP210103065A patent/AR123998A1/es unknown
-
2023
- 2023-04-20 CO CONC2023/0004963A patent/CO2023004963A2/es unknown
- 2023-04-25 ZA ZA2023/04779A patent/ZA202304779B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023548205A (ja) | 2023-11-15 |
| ZA202304779B (en) | 2024-09-25 |
| CO2023004963A2 (es) | 2023-06-20 |
| CA3197024A1 (en) | 2022-05-12 |
| CU24665B1 (es) | 2023-06-13 |
| CU20200081A7 (es) | 2022-06-06 |
| AU2021373188A1 (en) | 2023-06-01 |
| CN116802194A (zh) | 2023-09-22 |
| AR123998A1 (es) | 2023-02-01 |
| US20230405106A1 (en) | 2023-12-21 |
| WO2022096039A1 (es) | 2022-05-12 |
| EP4242222A1 (en) | 2023-09-13 |
| AU2021373188A9 (en) | 2024-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Park et al. | mRNA vaccines for COVID-19: what, why and how | |
| TWI620568B (zh) | 用於治療ｂ型肝炎及ｄ型肝炎感染之方法 | |
| BR112022015626A2 (pt) | Composição e métodos de vacinas de mrna contra infecção de novo coronavírus | |
| BR112012018529A2 (pt) | inibidores do vírus de hepatite c, sua composição farmacêutica e seu uso, e método para inibição da replicação de um vírus contendo rna | |
| SI3097102T1 (en) | Toll-like receptor modulating 4,6-diamino-pyrido(3,2-d)pyrimidine compounds | |
| Hayden | Advances in antivirals for non‐influenza respiratory virus infections | |
| Barkhouse et al. | Expression of interferon gamma by a recombinant rabies virus strongly attenuates the pathogenicity of the virus via induction of type I interferon | |
| EA202191537A1 (ru) | Композиции и способы ингибирования экспрессии генов вируса гепатита в | |
| IL276210B2 (en) | Mers-cov vaccine | |
| IL295630A (en) | Compositions and methods for inducing an immune response | |
| Wang et al. | Colloidal manganese salt improves the efficacy of rabies vaccines in mice, cats, and dogs | |
| BR112022010425A2 (pt) | Proteínas de ligação ao antígeno associadas a interferon para uso no tratamento de infecção por hepatite b | |
| AR088580A1 (es) | Metodos y composiciones para tratar el virus de la hepatitis c | |
| WO2008092854A3 (en) | Papillomavirus e2 polypeptide used for vaccination | |
| EA201300135A1 (ru) | Комбинированная фармацевтическая композиция и способы лечения и профилактики инфекционных заболеваний | |
| WO2021257510A3 (en) | Measles virus vaccine expressing sars-cov-2 protein(s) | |
| CA3174599A1 (en) | Improvements in vaccine formulations for medical use | |
| Dorfmeier et al. | Reinvestigating the role of IgM in rabies virus postexposure vaccination | |
| NZ602693A (en) | Immunogenic proteins and compositions for the treatment and prevention of streptococcus agalactiae | |
| MY207126A (en) | 4/91 ibv vaccine with heterologous spike protein | |
| ZA202304779B (en) | Chimeric protein comprising the receptor binding domain of the coronavirus spike protein and compositions comprising thereof | |
| Chaudhary et al. | The recent updates on approaches and clinical trials status of Covid-19 vaccines developed globally | |
| RU2016144379A (ru) | Фармацевтическая композиция для пассивной иммунизации против бешенства, фармацевтический набор, способ применения фармацевтического набора | |
| KR102784152B1 (ko) | 톨-유사 수용체 7 효능제를 유효성분으로 포함하는 구제역바이러스 억제용 조성물 및 이를 포함하는 아쥬반트 조성물 또는 구제역 백신 조성물 | |
| Lee et al. | Current advances in the development of vaccines and therapeutic agents against MERS-CoV |